Brad A Racette

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6980620/publications.pdf

Version: 2024-02-01

72 papers	3,382 citations	159585 30 h-index	149698 56 g-index
72 all docs	72 docs citations	72 times ranked	3906 citing authors

#	Article	IF	Citations
1	Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries. Neuroepidemiology, 2010, 34, 143-151.	2.3	330
2	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA - Journal of the American Medical Association, 2016, 316, 40.	7.4	327
3	Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurology, The, 2015, 14, 710-719.	10.2	243
4	Increased risk of parkinsonism associated with welding exposure. NeuroToxicology, 2012, 33, 1356-1361.	3.0	132
5	Metal Emissions and Urban Incident Parkinson Disease: A Community Health Study of Medicare Beneficiaries by Using Geographic Information Systems. American Journal of Epidemiology, 2010, 172, 1357-1363.	3.4	130
6	Predictors of Survival in Patients With Parkinson Disease. Archives of Neurology, 2012, 69, 601.	4.5	130
7	Pathophysiology of manganese-associated neurotoxicity. NeuroToxicology, 2012, 33, 881-886.	3.0	115
8	[18F]FDOPA PET and clinical features in parkinsonism due to manganism. Movement Disorders, 2005, 20, 492-496.	3.9	106
9	Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiology of Aging, 2016, 37, 209.e1-209.e7.	3.1	106
10	Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. American Journal of Medical Genetics Part A, 1999, 88, 539-543.	2.4	99
11	Basal ganglia intensity indices and diffusion weighted imaging in manganese-exposed welders. Occupational and Environmental Medicine, 2012, 69, 437-443.	2.8	98
12	Dose-dependent progression of parkinsonism in manganese-exposed welders. Neurology, 2017, 88, 344-351.	1.1	92
13	Nursing home and end-of-life care in Parkinson disease. Neurology, 2015, 85, 413-419.	1.1	87
14	Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. Neurology, 2012, 79, 1774-1780.	1.1	86
15	Manganism in the 21st century: The Hanninen lecture. NeuroToxicology, 2014, 45, 201-207.	3.0	64
16	Blood Manganese as an Exposure Biomarker: State of the Evidence. Journal of Occupational and Environmental Hygiene, 2014, 11, 210-217.	1.0	64
17	Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. Parkinsonism and Related Disorders, 2018, 50, 23-28.	2.2	61
18	Immunosuppressants and risk of Parkinson disease. Annals of Clinical and Translational Neurology, 2018, 5, 870-875.	3.7	61

#	Article	IF	Citations
19	Botulinum toxin B reduces sialorrhea in parkinsonism. Movement Disorders, 2003, 18, 1059-1061.	3.9	60
20	Î²2â€adrenoreceptor medications and risk of Parkinson disease. Annals of Neurology, 2018, 84, 683-693.	5.3	59
21	A predictive model to identify Parkinson disease from administrative claims data. Neurology, 2017, 89, 1448-1456.	1.1	47
22	Thalamic stimulation for primary writing tremor. Journal of Neurology, 2001, 248, 380-382.	3.6	41
23	Neuromythology of Manganism. Current Epidemiology Reports, 2015, 2, 143-148.	2.4	41
24	Estimation of Particulate Mass and Manganese Exposure Levels among Welders. Annals of Occupational Hygiene, 2011, 55, 113-25.	1.9	39
25	Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data. Annals of Neurology, 2017, 82, 744-754.	5.3	39
26	Quantitative neuropathology associated with chronic manganese exposure in South African mine workers. NeuroToxicology, 2014, 45, 260-266.	3.0	38
27	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). JAMA Neurology, 2016, 73, 102.	9.0	38
28	Clinical Features and Comorbidity of Mood Fluctuations in Parkinson's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 438-442.	1.8	37
29	Relative Mortality in U.S. Medicare Beneficiaries with Parkinson Disease and Hip and Pelvic Fractures. Journal of Bone and Joint Surgery - Series A, 2014, 96, e27.	3.0	36
30	Parkinson disease and cognitive impairment. Neurology: Clinical Practice, 2016, 6, 452-458.	1.6	34
31	Manganese exposure, parkinsonian signs, and quality of life in South African mine workers. American Journal of Industrial Medicine, 2020, 63, 36-43.	2.1	30
32	Validity and Reliability of an Occupational Exposure Questionnaire for Parkinsonism in Welders. Journal of Occupational and Environmental Hygiene, 2009, 6, 324-331.	1.0	28
33	Inducible nitric oxide synthase gene methylation and parkinsonism in manganese-exposed welders. Parkinsonism and Related Disorders, 2015, 21, 355-360.	2.2	28
34	AÂfixed-doseÂrandomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Research, 2013, 2, 150.	1.6	28
35	Selective D2 receptor PET in manganese-exposed workers. Neurology, 2018, 91, e1022-e1030.	1.1	27
36	MRI Signal Intensity and Parkinsonism in Manganese-Exposed Workers. Journal of Occupational and Environmental Medicine, 2019, 61, 641-645.	1.7	26

#	Article	IF	Citations
37	A Population-Based Study of Parkinsonism in an Amish Community. Neuroepidemiology, 2009, 33, 225-230.	2.3	24
38	Time to change the blind men and the elephant approach to Parkinson disease?. Neurology, 2015, 85, 190-196.	1.1	24
39	[18 F]FDOPA positron emission tomography in manganese-exposed workers. NeuroToxicology, 2018, 64, 43-49.	3.0	23
40	Severity of parkinsonism associated with environmental manganese exposure. Environmental Health, 2021, 20, 27.	4.0	23
41	Sensitivity and specificity of the finger tapping task for the detection of psychogenic movement disorders. Parkinsonism and Related Disorders, 2010, 16, 197-201.	2.2	20
42	Effects of parkinsonism on health status in welding exposed workers. Parkinsonism and Related Disorders, 2011, 17, 672-676.	2.2	20
43	Chorea and jaw-opening dystonia as a manifestation of Neurobehcet's syndrome. Movement Disorders, 2000, 15, 741-744.	3.9	18
44	Late-Onset neurodegeneration with brain iron accumulation type 1: Expanding the clinical spectrum. Movement Disorders, 2001, 16, 1148-1152.	3.9	18
45	Cognitive control dysfunction in workers exposed to manganeseâ€containing welding fume. American Journal of Industrial Medicine, 2017, 60, 181-188.	2.1	18
46	Use of medical care biases associations between Parkinson disease and other medical conditions. Neurology, 2018, 90, e2155-e2165.	1.1	17
47	A rapid method for mass screening for parkinsonism. NeuroToxicology, 2006, 27, 357-361.	3.0	14
48	Depression and anxiety in a manganese-exposed community. NeuroToxicology, 2021, 85, 222-233.	3.0	14
49	Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). Movement Disorders, 2002, 17, 1098-1100.	3.9	12
50	Ex vivo magnetic resonance imaging in South African manganese mine workers. NeuroToxicology, 2015, 49, 8-14.	3.0	12
51	Herpesvirus Infections and Risk of Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2020, 20, 97-103.	1.4	12
52	[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 245-249.	1.7	11
53	Well Water and Parkinsonâ€™s Disease in Medicare Beneficiaries: A Nationwide Case-Control Study. Journal of Parkinson's Disease, 2020, 10, 693-705.	2.8	9
54	Inflammatory bowel disease and risk of Parkinson's disease in medicare beneficiaries. Parkinsonism and Related Disorders, 2018, 57, 77.	2.2	8

#	Article	IF	Citations
55	Fractures in the prodromal period of Parkinson disease. Neurology, 2020, 94, e2448-e2456.	1.1	8
56	The impact of litigation on neurologic research. Neurology, 2006, 67, 2124-2128.	1.1	7
57	Environmental manganese exposure and cognitive control in a South African population. NeuroToxicology, 2022, 89, 31-40.	3.0	6
58	Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial. NeuroRehabilitation, 2022, 50, 33-46.	1.3	6
59	Transplant and risk of Parkinson disease. Parkinsonism and Related Disorders, 2019, 63, 149-155.	2.2	5
60	The reproducibility of urinary ions in manganese exposed workers. Journal of Trace Elements in Medicine and Biology, 2019, 51, 204-211.	3.0	5
61	Validation of Parkinsonâ€™s Disease-Related Questionnaires in South Africa. Parkinson's Disease, 2020, 2020, 1-9.	1.1	5
62	Validation of a Parkinson Disease Predictive Model in a Population-Based Study. Parkinson's Disease, 2020, 2020, 1-7.	1.1	5
63	Solvent exposed occupations and risk of Parkinson disease in Finland. Clinical Parkinsonism & Related Disorders, 2021, 4, 100092.	0.9	5
64	A comparison of prediction approaches for identifying prodromal Parkinson disease. PLoS ONE, 2021, 16, e0256592.	2.5	5
65	Physician response to a medication alert system in inpatients with levodopa-treated diseases. Neurology, 2015, 85, 420-424.	1.1	4
66	Parkinsonism Signs and Symptoms in Agricultural Pesticide Handlers in Washington State. Journal of Agromedicine, 2017, 22, 215-221.	1.5	4
67	Screening for early detection of parkinsonism using a self-administered questionnaire: A cross-sectional epidemiologic study. NeuroToxicology, 2014, 45, 232-237.	3.0	3
68	A screening tool to detect clinical manganese neurotoxicity. NeuroToxicology, 2018, 64, 12-18.	3.0	3
69	[11C]dihydrotetrabenazine Positron Emission Tomography in Manganese-Exposed Workers. Journal of Occupational and Environmental Medicine, 2020, 62, 788-794.	1.7	3
70	Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese-Exposed Workers. Toxicological Sciences, 2021, 182, 132-141.	3.1	3
71	A Rapid Motor Task-Based Screening Tool for Parkinsonism in Community-Based Studies. Frontiers in Neurology, 2021, 12, 653066.	2.4	1
72	Author response: A predictive model to identify Parkinson disease from administrative claims data. Neurology, 2018, 91, 104-104.	1.1	0